JP Morgan Healthcare Conference - Ipsen Group · 2017-01-12 · 2 Goldman Sachs 35th Annual Global Healthcare Conference –June 2014 2 Ipsen – 2017 JP Morgan Healthcare Conference

IPSEN pour nom de la société - 07/04/2011 / page 1

January 11, 2017

Ipsen

JP Morgan Healthcare Conference

2 Goldman Sachs 35th Annual Global Healthcare Conference – June 2014 Ipsen – 2017 JP Morgan Healthcare Conference 2 2

Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates

contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements involve known

and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary

information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new

product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on

the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic

that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any

obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change

in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners.

The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with

the specific procedures, terms and conditions set forth by each national legislation.

Safe Harbor The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current

crisis, which could in turn erode the local competitiveness of the Group’s products relative to competitors operating in local currency, and/or could be

detrimental to the Group’s margins in those regions where the Group’s drugs are billed in local currencies.

In a number of countries, the Group markets its drugs via distributors or agents: some of these partners’ financial strength could be impacted by the

crisis, potentially subjecting the Group to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is

threatened by the crisis and where the Group sells its drugs directly to hospitals, the Group could be forced to lengthen its payment terms or could

experience difficulties in recovering its receivables in full.

Finally, in those countries in which public or private health cover is provided, the impact of the financial crisis could cause medical insurance agencies

to place added pressure on drug prices, increase financial contributions by patients or adopt a more selective approach to reimbursement criteria.

All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic

conditions based on the information available today.


Agenda

2 Merrimack transaction accelerates Ipsen’s

Oncology strategy

1 Business update:

Accelerated momentum driving transformation

3 Establishing leadership in Oncology

4 Building long-term value in Neurosciences

Business update:

Accelerated momentum driving transformation


Eventful year propelling Ipsen forward

1The Merrimack transaction is subject to customary closing conditions, including governmental regulatory clearances, and approval by Merrimack shareholders

Cabozantinib in-licensing

U.S. becomes #1

affiliate New CEO

Cabometyx®

EU approval Merrimack

transaction1

February 2016 June 2016 July 2016 September 2016 January 2017

Underlying strong double-digit revenue growth

Growing Oncology focus

David Meek

https://www.google.co.uk/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjo26DG1vjQAhUGOhoKHZQ1ABcQjRwIBw&url=https://www.onivyde.com/&psig=AFQjCNH9bWMgXQ0zPIUZDttniuFmPOosVw&ust=1481976425132155


Accelerated strategy driving long-term growth and increased profitability

Strong operating performance driven by Somatuline® for NET in U.S.

Cabometyx® launch in Europe supported by strong clinical profile

Onivyde® transaction to leverage U.S. commercial infrastructure

Long-term

growth

& increased

profitability

Building on the

foundation of

10%+ growth

Accelerating mid-

term growth

Increasing

operating

leverage

Building global oncology platform

Note: NET: Neuroendocrine Tumors

Merrimack transaction accelerates Ipsen’s

Oncology strategy


- Key product ONIVYDE®

Approved for the treatment of patients with metastatic pancreatic

cancer following gemcitabine-based therapy, in combination with

fluorouracil and leucovorin

- Generic doxorubicin HCl liposome injection

Acquisition of oncology assets from Merrimack Pharmaceuticals

$575m cash at closing and up to $450m upon FDA approval of additional

indications in the U.S.

Rights for current and potential future ONIVYDE indications

in the United States

Ex-U.S. rights held by Shire through a licensing agreement

(and PharmaEngine in Taiwan)

Wholly-owned

product

Infrastructure Manufacturing and commercial structure



Accelerating transformation of Ipsen

Strengthening Oncology focus

• Emerging as recognized market leader in several specialized markets

• Global oncology currently representing >50% of sales

• New oncology products important growth contributor

Growing U.S. presence

• U.S. establishing meaningful presence in oncology market

• Oncology commercial team has strong expertise and a proven track record

• Leveraging current infrastructure to optimize resources

Increasing growth and profitability

Transactions over the last 12 months have accelerated Ipsen’s transformation

into a leading global specialty care company with a growing Oncology franchise

• Substantial synergies to further leverage profitability with limited short-term dilution

• Accretive from 2018 to Ipsen’s growth, profitability and earnings

• Supporting confidence to achieve longer-term goals and sustained profitability


Differentiated product for metastatic pancreatic cancer

ONIVYDE: New product in a tumor with high unmet medical need with overall survival data and established safety profile

Note: IP: Intellectual Property; NCCN: National Comprehensive Cancer Network; FU/LV = fluorouracil/ leucovorin; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression-Free Survival; PK: Pharmacokinetics ; TTF: Time to Treatment Failure

First and only FDA-approved therapy in post-gemcitabine

pancreatic cancer

Novel encapsulation of irinotecan

Superior PK profile

Selective accumulation at tumor site

Market exclusivity until 2028

Strong clinical profile in NAPOLI-1 study published in Lancet

ONIVYDE + 5-FU/LV significantly improved OS among patients

previously treated with gemcitabine-based therapy

Superior PFS, ORR and TTF in patients receiving ONIVYDE + 5-

FU/LV

Category 1 evidence in NCCN guidelines for 2L treatment

https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=imgres&cd=&cad=rja&uact=8&ved=0ahUKEwj6koqLpLHRAhXJsFQKHWbyD_kQjRwIBw&url=https://plus.google.com/u/0/116212407920373928457&psig=AFQjCNHykd7LqGfA-R6fcbHg7mVMu2YPQg&ust=1483921387363555

https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjkn8qbpbHRAhXErFQKHcjFD8gQjRwIBw&url=https://www.atthelimits.org/home/the-lancet/&bvm=bv.142059868,d.cGw&psig=AFQjCNFPCog2xr5E_GAnfBSmYg1NRnAwyw&ust=1483921633312117



Pancreatic Cancer Patients (1)

Adjuvant / Neoadjuvant

Front-Line Metastatic

Second-Line Metastatic

Third-Line + Metastatic

~50,000

ONIVYDE-eligible patients

Metastatic pancreatic cancer

Disease progression following

gemcitabine

Resectable? Yes -- Surgery

No –

Treatment

(1) National Comprehensive Cancer Network.

ONIVYDE approved for the treatment of

patients with metastatic adenocarcinoma of

the pancreas after disease progression

following gemcitabine-based therapy,

in combination with fluorouracil and

leucovorin

Significant commercial opportunity in metastatic pancreatic cancer in the U.S.


Current team with extensive experience in oncology

Track record of successfully launching to key stakeholders in the

pancreatic cancer market, making ONIVYDE a natural fit

Team of over 130 dedicated (sales, marketing, reimbursement, medical

affairs, patient services, GPO, payer services, HEOR) with deep oncology

experience, well-positioned to take on new opportunity in the space

Note: GPO: Group Purchasing Organization; HEOR: Health Economics and Outcomes Research

U.S. oncology commercial organizational expertise to accelerate growth trajectory and maximize product potential

Establishing leadership

in specialty Oncology markets


Mature but growing product in EU and ROW

(China)

Best-in-class SSA leadership position in NET

market

Ongoing EU launch in 2L

RCC supported by strong

clinical profile

Differentiated product for high unmet medical

need

* *

Ipsen establishing global leadership in specialty Oncology markets

* Including U.S. commercial rights

Prostate

Cancer

Neuroendocrine

Tumors (NET)

Renal Cell

Carcinoma

Pancreatic

Cancer

Growing U.S. Oncology presence



Note: TKI: Tyrosine Kinase Inhibitor; PFS: Progression Free Survival; OS: Overall Survival; ORR: Objective Response Rate; HCC: Hepatocellular Carcinoma

Oral small molecule TKI

targeting multiple receptors

Inhibits tumor angiogenesis,

metastasis, drug resistance

Multi-targeted approach

of three distinct molecular

pathways

E

Positive results in Phase 2

CABOSUN trial for 1L RCC

CELESTIAL Phase 3

trial in 2L HCC

Additional programs in other

indications and as

combination therapy

Phase 3 METEOR trial:

Clinically meaningful

improvements:

PFS, OS, ORR

Encouraging P3 subgroup

analysis showing benefit

across all patient types

Inclusion in U.S. and EU

2L RCC treatment guidelines

Unique and effective mechanism of action

Ongoing development

program Robust clinical profile

Cabometyx®: Next-generation product for Renal Cell Carcinoma (RCC)

Exclusive ex-U.S., ex-Japan commercialization rights


Hiring experienced

Oncology commercial team

Preparation of market access submissions

EU approval

Early access

program initiated

Ongoing launches

country by country:

Germany, France, UK…

Supported by:

Strong clinical profile,

treatment guidelines

September 2016

November 2016

March - September 2016

Launch phase

Cabometyx® EU launch excellence to drive momentum

Launch readiness


Key therapy for 1st line NET

Establishing leadership in Neuroendocrine Tumor (NET) market

Note: IP: Intellectual Property; SSA: Somatostatin analogue (1) Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence – SEER

18 Regs Research Data, Nov 2011

Strong clinical profile of enhanced,

ready-to-use subcutaneous device

FDA regulatory decision for symptom

control in the U.S.

Ongoing Phase 3 trial in lung NET

3-month formulation under development

IP protection in the U.S. until 2020

Expansion of U.S. market to over $1bn since

Somatuline NET launch in early 2015

Over 5x increase in NET incidence over last

40 years(1)

Growth from previously untreated “watch and

wait” patients on therapy

Ipsen presence in major treatment centers

Substantial U.S. market opportunity

Added to SSA therapy for carcinoid syndrome not adequately controlled by long-acting SSA

EU approval expected mid-2017

Complementary product to Somatuline to expand NET franchise along treatment paradigm

Lifecycle management

Telotristat ethyl : 2nd line therapy


Somatuline®: Ipsen’s largest product and largest contributor of growth

(1) Growth rate for first nine months of 2016 (2) Estimate for FY 2016 based on performance of first nine months of 2016

0

100

200

300

400

500

600

2014 2015 2016E (2)

€mn

+40%

+36%(1)

Strong global momentum

U.S. fastest growing market

Market share gains in the U.S.

#1 SSA in some key EU markets

Net sales 2014-2016E

Building long-term value in Neurosciences


Worldwide presence in attractive neurotoxin market

Worldwide botulinum toxin market : ~$3.0bn

• Geography: ~50% U.S. / ~50% ex-U.S.

• Indication: ~50% therapeutics / ~50% aesthetics

• Attractive annual market growth at high-single digit percent

• Dysport: #1 or #2 position in most markets

Therapeutics market

Focus on spasticity indication

Europe: More mature and developed market

U.S.: Ongoing launch in new indications

Development of next-generation toxins

Aesthetics market

Successful partnership with Galderma for

commercialization and R&D

Territories: >75% of world aesthetics

Ongoing geographic expansion


U.S. Dysport Therapeutics: New spasticity launches increase market opportunity

Building critical mass of indications to increase market share

Approved

indications

Cervical Dystonia

Indications in

development

AUL spasticity

PLL spasticity

ALL spasticity

Launched 2016

Expected launch 2017

PUL spasticity Expected launch 2018+

~ $400m

Note: ALL: Adult Lower Limb; AUL: Adult Upper Limb; PLL: Pediatric Lower Limb; PUL: Pediatric Upper Limb

Launched 2009

Launched 2015

~ $100m

Addressable

market


Roadmap to increased and sustained growth and profitability

Accelerated business momentum driving transformation

Delivering superior value to patients and shareholders

Establishing leadership position with integration of new Oncology assets

Cabometyx®, Onivyde®

Solid operating performance fueled by Somatuline® and U.S. growth

Executing Primary Care shift to OTx commercial model

Thank you

Documents

JP Morgan Healthcare Conference - Ipsen Group · 2017-01-12 · 2 Goldman Sachs 35th Annual Global Healthcare Conference –June 2014 2 Ipsen – 2017 JP Morgan Healthcare Conference